Pure Bioscience (PURE) Price & Analysis

Compare

44 Followers

PURE Stock Chart & Stats

$0.05

<$0.01(1.96%)

At close: Jan 08 4:00 PM EST

$0.05

<$0.01(1.96%)

Day’s Range― - ―

52-Week Range$0.04 - $0.21

Previous CloseN/A

Volume1.63K

Average Volume (3M)53.72K

Market Cap

$9.17M

Enterprise Value$15.12M

Total Cash (Recent Filing)$198.00K

Total Debt (Recent Filing)$6.14M

Price to Earnings (P/E)―

Beta-0.30

Next Earnings

Jun 16, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding111,886,475

10 Day Avg. Volume24,352

30 Day Avg. Volume53,720

Financial Highlights & Ratios

PEG Ratio0.15

Price to Book (P/B)>-0.01

Price to Sales (P/S)0.00456

P/FCF Ratio>-0.01

Enterprise Value/Market Cap1.65

Enterprise Value/Revenue6.28

Enterprise Value/Gross Profit0.01

Enterprise Value/Ebitda-8.42

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue GrowthSustained ~31% reported revenue growth indicates the company can expand product adoption and market reach for its SDC disinfectant offerings. If the company can stabilize sales cadence, persistent top-line growth supports scaling fixed-cost absorption and improves the path toward durable profitability.

Strong Historical Gross MarginsAnnual gross margins near the mid-50s percent point to attractive unit economics for the core antimicrobial chemistry. Strong product-level margins create structural leverage: with higher and steadier revenues, the company can fund operating expenses and improve operating leverage towards sustainable profitability.

Financing Flexibility Via Share AuthorizationExpanded authorized shares give management durable flexibility to raise equity, grant compensation, or pursue strategic transactions. That structural option reduces immediate solvency pressure by enabling capital raises to support operations or strategic investments when cash generation remains weak.

Bears Say

Negative Shareholder EquitySustained negative equity signals a materially weakened capital structure and limits financial flexibility. Over months this raises refinancing risk, can restrict access to credit or favorable vendor terms, and makes the business more reliant on dilutive equity or costly debt to fund operations.

Persistent Cash BurnConsistent negative operating and free cash flow means the company cannot self-fund growth or cover operating needs over the medium term. Continued cash burn increases dependence on external financing, raising dilution or insolvency risk and constraining capacity to invest in commercial expansion.

Revenue Volatility & UnprofitabilityExtreme revenue swings and persistent losses hamper forecasting, margin consistency, and strategic planning. Volatility undermines the ability to demonstrate repeatable demand, making it harder to convert margin advantages into sustained net profitability and increasing execution risk over the next several quarters.

Pure Bioscience News

Pure Bioscience Shareholders Back Governance, Expand Stock Authorization

Pure Bioscience ( ($PURE) ) has provided an update. Pure Bioscience, Inc. held its Annual Meeting of Stockholders...

1M ago

PURE

PURE Bioscience Announces New Leadership Appointments

The latest announcement is out from Pure Bioscience ( ($PURE) ). On November 19, 2025, PURE Bioscience, Inc....

4M ago

PURE

PURE Bioscience and AFCO, a Zep Company in distribution deal for SDC products

PURE Bioscience (PURE) and AFCO, a Zep Company, have entered into a multi-year distribution agreement for the purchase...

1y ago

PURE

PURE Bioscience enters distribution agreement with Madison Chemical

PURE Bioscience (PURE) and Madison Chemical Co. have entered into a multi-year distribution agreement for the purchase and...

1y ago

PURE

PURE Bioscience announces SDC distribution agreement with Zee Company

PURE Bioscience has entered into a multi-year distribution agreement with Tennessee-based Zee Company to purchase and sell PURE‘s...

1y ago

PURE

PURE Bioscience enters international supply, license agreement with AgroVet

PURE Bioscience and AgroVet Alliance have entered into a multi-year international supply and license agreement for the purchase...

2y ago

PURE

PURE FAQ

What was Pure Bioscience’s price range in the past 12 months?

Pure Bioscience lowest stock price was $0.04 and its highest was $0.21 in the past 12 months.

What is Pure Bioscience’s market cap?

Pure Bioscience’s market cap is $9.17M.

When is Pure Bioscience’s upcoming earnings report date?

Pure Bioscience’s upcoming earnings report date is Jun 16, 2026 which is in 84 days.

How were Pure Bioscience’s earnings last quarter?

Pure Bioscience released its earnings results on Mar 16, 2026. The company reported -$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.007.

Is Pure Bioscience overvalued?

According to Wall Street analysts Pure Bioscience’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Pure Bioscience pay dividends?

Pure Bioscience does not currently pay dividends.

What is Pure Bioscience’s EPS estimate?

Pure Bioscience’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Pure Bioscience have?

Pure Bioscience has 111,886,475 shares outstanding.

What happened to Pure Bioscience’s price movement after its last earnings report?

Pure Bioscience reported an EPS of -$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Pure Bioscience?

Currently, no hedge funds are holding shares in PURE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Pure Bioscience

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.